Tki Treatment Discontinuation: How Many Patients Could Stop Tyrosine Kinase Treatment According To Discontinuation Trials Criteria? Incidence And Prognostic Impact Of Deep Molecular Response In A Cohort Of Chronic Myeloid Leukemia Patients Of South Brazil'S Hematology Centers
BLOOD(2014)
Abstract
Sustained deep molecular response (MR4.5) after imatinib treatment defines a subgroup of patients with chronic myeloid leukemia (CML) with better outcome and that probably would be able to stop treatment in the future, according to results of clinical TKI discontinuation trials. Most of these trials showed that patients with a long-term imatinib treatment and low Sokal risk have a higher probability of maintain a deep molecular remission after stopping treatment.
MoreTranslated text
Key words
tyrosine kinase treatment,tki treatment discontinuation,chronic myeloid leukemia patients,chronic myeloid leukemia
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined